A FISH assay efficiently screens for BRAF gene rearrangements in pancreatic acinar-type neoplasms

  title={A FISH assay efficiently screens for BRAF gene rearrangements in pancreatic acinar-type neoplasms},
  author={L. Wang and O. Basturk and Jiajing Wang and R. Benayed and S. Middha and A. Zehir and I. Linkov and Mamta Rao and R. Aryeequaye and Long Cao and J. Chmielecki and J. Ross and P. Stephens and V. Adsay and G. Askan and Serdar Balci and D. Klimstra},
  journal={Modern Pathology},
Approximately 1–2% of pancreatic neoplasms are acinar cell carcinomas. Recently, BRAF gene rearrangements were identified in over 20% of acinar-type neoplasms, which included both pure acinar cell carcinomas and mixed carcinomas with acinar differentiation, using next-generation sequencing-based platforms, providing a potential therapeutic target for patients with these neoplasms. Thus, it is clinically important to develop a rapid, cost- and material-efficient assay to screen for BRAF gene… Expand
RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas
RAF1 rearrangements are common in pancreatic acinar cell carcinomas
Successful BRAF/MEK inhibition in a patient with BRAFV600E-mutated extrapancreatic acinar cell carcinoma
Pancreatic Neoplasms With Acinar Differentiation: A Review of Pathologic and Molecular Features.
Acinar cell carcinoma of the pancreas: a clinicopathologic and cytomorphologic review.


The distribution of BRAF gene fusions in solid tumors and response to targeted therapy
Pathology and genetics of pancreatic neoplasms with acinar differentiation.
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.
Acinar neoplasms of the pancreas-A summary of 25 years of research.